Benzinga | Sep 1, 2020 04:30PM EDT

Aerpio And Quantum Leap Announce First Patients Dosed With Razuprotafib In I-SPY COVID Trial To Treat ARDS In Critically-ill COVID-19 Patients

SAN FRANCISCO and CINCINNATI, Sept. 1, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) and Quantum Leap Healthcare Collaborative(tm) (Quantum Leap) announced today dosing of the first patient with razuprotafib in the I-SPY COVID Trial (NCT04488081), a phase 2 platform trial aimed at improving treatment of acute respiratory distress syndrome (ARDS) in severely ill COVID-19 (adult) patients. Further details about the study can be found here.